Redefining
Regenerative
Medicine

Histogen is a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body. This innovative technology utilizes human proteins and growth factors produced by hypoxia-induced multipotent cells to address what Histogen believes to be underserved, multibillion dollar global markets.

ABOUT

clinical programs

Histogen is advancing three clinical programs in therapeutic indications with large commercial market opportunities:

HAIR GROWTH

Hair Growth

A minimally-invasive treatment that is intended to grow new hair, not simply preserve existing hair.

 
SKIN CARE

Dermal Fillers

Human-derived collagen and extracellular matrix dermal fillers delivering potentially longer-lasting effects with fewer side effects for the treatment of facial folds and wrinkles.

 
MATRIX REGENERATION

Joint Cartilage Repair

Histogen’s extracellular matrix for articular cartilage defects regenerates hyaline cartilage for the treatment of knee osteoarthritis with a novel malleable scaffold produced by the body’s own stem cells.

 

Latest News

May 28, 2020
Histogen Appoints Susan A. Knudson as Chief Financial Officer

SAN DIEGO , May 28, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the appointment of Susan A. Knudson as Executive Vice President and Chief Financial Officer.

Read more
May 27, 2020
Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the completion of its previously disclosed merger with Conatus Pharmaceuticals Inc.  The

Read more
May 18, 2020
Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split

SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory firms that provide institutional investors with voting assessment and

Read more
View All